BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Rating) has been given an average rating of "Moderate Buy" by the nine analysts that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $52.89.
Several analysts have weighed in on the stock. HC Wainwright dropped their price objective on shares of BioXcel Therapeutics from $85.00 to $73.00 and set a "buy" rating for the company in a research note on Tuesday, January 3rd. Canaccord Genuity Group boosted their target price on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the company a "buy" rating in a research report on Friday, November 11th. Mizuho boosted their target price on shares of BioXcel Therapeutics from $18.00 to $24.00 in a research report on Thursday, December 15th. Guggenheim dropped their target price on shares of BioXcel Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research report on Friday, November 11th. Finally, Canaccord Genuity Group boosted their target price on shares of BioXcel Therapeutics from $75.00 to $76.00 and gave the company a "buy" rating in a research report on Friday, November 11th.
Get BioXcel Therapeutics alerts:Insiders Place Their Bets
In other BioXcel Therapeutics news, insider Frank Yocca sold 50,000 shares of the business's stock in a transaction that occurred on Friday, January 20th. The shares were sold at an average price of $30.00, for a total transaction of $1,500,000.00. Following the sale, the insider now directly owns 8,397 shares of the company's stock, valued at approximately $251,910. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Krishnan Nandabalan sold 27,450 shares of the company's stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $15.00, for a total value of $411,750.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Frank Yocca sold 50,000 shares of the company's stock in a transaction on Friday, January 20th. The shares were sold at an average price of $30.00, for a total transaction of $1,500,000.00. Following the completion of the sale, the insider now directly owns 8,397 shares in the company, valued at $251,910. The disclosure for this sale can be found here. Insiders have sold 133,339 shares of company stock valued at $3,073,310 in the last ninety days. 37.00% of the stock is currently owned by insiders.
Institutional Investors Weigh In On BioXcel Therapeutics
Institutional investors have recently modified their holdings of the company. Millennium Management LLC lifted its position in shares of BioXcel Therapeutics by 872.6% during the 2nd quarter. Millennium Management LLC now owns 188,548 shares of the company's stock valued at $2,489,000 after acquiring an additional 169,163 shares during the period. Nuveen Asset Management LLC raised its holdings in BioXcel Therapeutics by 95.5% during the third quarter. Nuveen Asset Management LLC now owns 217,624 shares of the company's stock worth $2,572,000 after buying an additional 106,314 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in BioXcel Therapeutics by 330.5% during the first quarter. Dimensional Fund Advisors LP now owns 125,280 shares of the company's stock worth $2,620,000 after buying an additional 96,180 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in BioXcel Therapeutics by 569.9% during the second quarter. Cubist Systematic Strategies LLC now owns 91,039 shares of the company's stock worth $1,202,000 after buying an additional 77,449 shares during the last quarter. Finally, State Street Corp raised its holdings in BioXcel Therapeutics by 4.1% during the first quarter. State Street Corp now owns 1,400,753 shares of the company's stock worth $29,290,000 after buying an additional 55,657 shares during the last quarter. 42.35% of the stock is owned by institutional investors.BioXcel Therapeutics Price Performance
Shares of BioXcel Therapeutics stock opened at $31.66 on Wednesday. BioXcel Therapeutics has a twelve month low of $8.80 and a twelve month high of $32.96. The company has a quick ratio of 10.28, a current ratio of 10.34 and a debt-to-equity ratio of 0.72. The company has a 50-day simple moving average of $22.02 and a two-hundred day simple moving average of $16.54. The stock has a market capitalization of $887.11 million, a price-to-earnings ratio of -6.47 and a beta of 1.16.
BioXcel Therapeutics (NASDAQ:BTAI – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.15). The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $3.05 million. Analysts forecast that BioXcel Therapeutics will post -5.37 EPS for the current year.
About BioXcel Therapeutics
(Get Rating)
BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Featured Stories
- Get a free copy of the StockNews.com research report on BioXcel Therapeutics (BTAI)
- Can Yext A.I. Search Platform Drive Growth in 2023?
- Cassava Sciences Stock Undervalued with Its $124 Price Target?
- Constellation Brands: Are Consumers Trading Down for Rail Drinks?
- Capital One Stock: Will Subprime Borrowers Spoil the Rally?
- MarketBeat Week in Review – 1/23- 1/27
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.